NCT00648999 - Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

Human Immunodeficiency Virus

Interventions

DRUG

lopinavir/ritonavir

lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment

Trial Locations (13)

Site Ref # / Investigator 4077, Mexico City

Site Ref # / Investigator 4073, Chihuahua City

Site Ref # / Investigator 4053, Puebla City

Site Ref # / Investigator 4075, Mérida

Site Ref # / Investigator 4074, León

Site Ref # / Investigator 4056, Mexico City

Site Ref # / Investigator 4054, Morelia

Site Ref # / Investigator 4072, Tepic

Site Ref # / Investigator 4052, Oaxaca City

Site Ref # / Investigator 4055, Culiacán

Site Ref # / Investigator 4049, Mexico City

Site Ref # / Investigator 4050, Mexico City

Site Ref # / Investigator 4051, Mexico City

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY